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Introduction
Gabapentin and pregabalin, commonly known as gabapentinoids, have been widely used globally. Gabapentin is an anticonvulsant agent used in treating various illnesses such as amyotrophic lateral sclerosis, analgesia, anxiety, neuralgia, restless legs syndrome and bipolar disorder 1 . Pregabalin is commonly used for the treatment of painful diabetic neuropathy, fibromyalgia, diabetic neuropathy, cancer chemotherapy-induced neuropathic pain, post-herpetic neuralgia, trigeminal neuralgia, and post-operative pain 2, 3 . Pregabalin also acts to be an effective treatment therapy in refractory partial-onset seizures and the existing data recommends that pregabalin may be favorable as adjunctive therapy in adults with generalized or social anxiety disorder 3 .
As per the available safety data, the use of gabapentin and pregabalin may cause neuropsychiatric related adverse drug reactions (ADRs) followed by hepatic, cutaneous and hematological reactions 4 . Suicidal ideation, cognitive impairment, motor incoordination, dizziness are also severe forms of ADRs associated with gabapentinoids 5 . The use of pregabalin is associated with hematological ADRs and gabapentin is also associated with liver toxicity.
Respiratory concerns with gabapentin and pregabalin
Respiratory depression, a highly mortal condition, due to gabapentin and pregabalin has been emerging for the past few years even in patients who were not on opioids, though post-marketing studies showed similar effects among patients taking these medications concurrently along with other respiratory suppressants 6 . In December 2019, the United States Food and Drug Administration (US FDA) issued a drug safety alert on serious breathing problems with gabapentin and pregabalin noticed when used along with central nervous system (CNS) depressants or in patients with lung problems. US FDA reviewed data from the FDA Adverse Event Reporting System (FAERS) 7 database of almost five years, i.e. from January 1, 2012 -October 26, 2017, which revealed 49 cases of gabapentinoid-induced respiratory depression. Out of 49, the majority of cases (n=34; 69.3%) were reported with pregabalin and 30.6% (n=15) cases were reported with gabapentin. Of these cases, 92% reported either a respiratory risk factor, including age-related loss of lung function, or the use of a CNS depressant. This report also revealed that 24% percent (n=12) of the 49 patients with respiratory depression died due to respiratory depression and were taking gabapentinoids.
What do the recent respiratory problems of gabapentin and pregabalin mean for pharmacovigilance in the developing world?
Since these ADR reports are from developed countries, it is difficult for regulators in developing countries to take decisions on these two medications that are also abundantly used in the developing world. For example, in India, there are escalating sales of gabapentin and pregabalin and while comparing the sales in 2017 to those in 2019, it was found that sales of gabapentin and pregabalin increased by 25% and 16%, respectively 8 .
As is well documented in the literature 9-11 , pharmacovigilance programs in developing countries lack robust reporting of ADRs and underreporting is a common issue. In order to bring any regulatory changes such as labeling changes or even ultimately banning the medications, one needs evidence, which largely is lacking at this point in time among developing countries 12 .
There have often been issues like this in the past where safety concerns emerge, largely from the developed world, with drugs like selective cyclooxygenase-2 inhibitors (coxibs) 13 , cerivastatin 14 and glitazones 15 , and the developing world, due to lack of stringent pharmacovigilance mechanisms, is left with little or no choice but to follow the actions taken by the developed world. In addition, developing countries lack options for communicating pharmacovigilance information 16 among key stakeholders including consumers, which is another concern. It is astonishing that many developing countries where large quantities of medicines are used still lack strong mechanisms to monitor the safety of their products.
Recommendations
In the current scenario, safety reports of gabapentinoids should be obtained from concerned manufacturers and reviewed for respiratory depression effects. As understood, manufacturers are an important partner in the pharmacovigilance process with the unique advantage of formulation related information. The periodic safety update reviews (PSURs) submitted by the manufacturers of gabapentanoids can be an important source for new signal detection 17 . In addition, the pharmaceutical manufacturer also has an obligation to report serious ADRs to the regulatory authorities 18 .
Healthcare professionals should be watchful and report ADRs associated with gabapentinoids. Spontaneous reporting of suspected ADRs in the past have been crucial in detecting ADRs at an early stage 19 .
Labeling changes should be made and a drug can be banned if needed 20 . New warnings are necessary to incorporate into prescribing information including package inserts about possible respiratory depression 8 . Concurrent use of these drugs with other respiratory depressants should be strictly monitored. Anecdotal reports on these medications should be encouraged as they can be crucial in the detection of ADRs 21 . If noticed, causality and severity assessments should be made for the suspected ADRs.
The patients on these two medications (and the ones closely chemically related to them) should be provided with proper counseling. Educating patients can help in the early detection of ADRs and active participation of patients can help in the identification of adverse events and ADRs, description of ADRs, and ultimately prevention of drug-related harm 22 . Hospital drug and therapeutics committees have a crucial role to play in situations like this by disseminating information within the hospital 23 . Social media may also play a crucial role in the signal generation of suspected ADRs in these situations 24 . Hospitals using these medications should develop risk management plans associated with gabapentoinoids usage and must disseminate any safety issues to concerned authorities.
Conclusions
Drug safety is a constantly evolving process and one must be constantly vigilant on the use of these medications. Healthcare professionals, especially prescribing physicians, nurses and pharmacists should be more cautious about using these medications in vulnerable people. Patient education and prescription restrictions of gabapentin and pregabalin may be needed until more data are available.
